Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9848723 | 0.85 | ALDH1A1 (0.40) | ALDH1A1CA1CA12CA2CA7 | |
| SCHEMBL5281509 | 0.83 | SMPD1 (0.44) | ALDH1A1CA1CA12CA2CA7 | |
| SCHEMBL5273914 | 0.81 | SMPD1 (0.47) | CA1CA12CA2CA7CA14 | |
| SCHEMBL5278349 | 0.81 | SMPD1 (0.47) | CA1CA12CA2CA7CA14 | |
| SCHEMBL27291509 | 0.80 | ALDH1A1 (0.40) | ALDH1A1CA1CA12CA2CA7 | |
| SCHEMBL14779173 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CA1CA12CA2CA7 | |
| SCHEMBL4998468 | 0.79 | ALDH1A1 (0.43) | ALDH1A1CA1CA12CA2CA7 | |
| SCHEMBL28760408 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CA1CA12CA2CA7 | |
| SCHEMBL28376461 | 0.77 | ALDH1A1 (0.42) | ALDH1A1USP2TSHR | |
| SCHEMBL4446331 | 0.77 | ALDH1A1 (0.48) | ALDH1A1CA1CA12CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3238709-B1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO LTD (US) | 2020-07-01 | — | — | EP | claimed |
| EP-3238709-A1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO, LTD. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-2701684-B1 | IMPROVED PARENTERAL FORMULATIONS OF LIPOPHILIC PHARMACEUTICAL AGENTS AND METHODS FOR PREPARING AND USING THE SAME | PLATFORM BRIGHTWORKS TWO LTD (US) | 2017-06-14 | — | — | EP | claimed |
| US-6927001-B1 | Non-aqueous electrolytic solution and lithium secondary battery | UBE INDUSTRIES, LTD. (JP) | 2005-08-09 | — | — | US | claimed |
| US-10665897-B2 | Lithium secondary battery including phosphite additive | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2020-05-26 | — | — | US | disclosed |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2020-05-26 | — | — | US | disclosed |
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2019-10-08 | — | — | US | disclosed |
| CN-105503732-B | For absorbing SO2Double imidazole ion liquids of ether and preparation method thereof and application method | 河北科技大学 | 2018-08-10 | — | — | CN | disclosed |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2018-08-02 | — | — | US | disclosed |
| EP-3315531-A1 | 8-ARM POLYETHYLENE GLYCOL DERIVATIVE, MANUFACTURING METHOD AND MODIFIED BIO-RELATED SUBSTANCE THEREBY | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2018-05-02 | — | — | EP | disclosed |
| US-20180053967-A1 | LITHIUM SECONDARY BATTERY INCLUDING PHOSPHITE ADDITIVE | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-02-22 | — | — | US | disclosed |
| CN-105498452-B | For absorbing SO2Double imidazole ion liquids of support type ether and preparation method thereof and application method | 河北科技大学 | 2018-02-06 | — | — | CN | disclosed |
| US-20030026801-A1 | Methods for enhancing antibody-induced cell lysis and treating cancer | PFIZER INC. | 2003-02-06 | — | — | US | disclosed |
| EP-1280907-A2 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS-SINAI MEDICAL CENTER (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1261620-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | Roche Diagnostics Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| US-20020156033-A1 | Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer | COLEY PHARMACEUTICAL GROUP, INC. | 2002-10-24 | — | — | US | disclosed |
| WO-2001088116-A9 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS SINAI MEDICAL CENTER (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2001097843-A2 | METHODS FOR ENHANCING ANTIBODY-INDUCED CELL LYSIS AND TREATING CANCER | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001088116-A2 | METHOD OF MODULATING ACTIVATION OF LYMPHOCYTES VIA MODULATION OF PITUITARY TUMOR TRANSFORMING GENE, RELATED SCREEINING METHODS | CEDARS-SINAI MEDICAL CENTER (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001057064-A2 | CATIONIC AMPHIPHILES FOR USE IN NUCLEIC ACID TRANSFECTION | ROCHE DIAGNOSTICS CORPORATION (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10434182-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, MRPS18A | ALDH1A1 1103/4885CA1 2605/4885CA12 1490/4885 |
| US-10660969-B2 | Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof | MRPL38, ALG8, COG8 | ALDH1A1 787/4885CA1 2620/4885CA12 1620/4885 |
| US-20180214561-A1 | EIGHT-ARM POLYETHYLENE GLYCOL DERIVATIVE, PRODUCTION METHOD THEREFOR, AND MODIFIEDBIO-RELATEDSUBSTANCETHEREOF | MRPL38, CXCL8, ALG8 | ALDH1A1 1061/4885CA1 2687/4885CA12 805/4885 |
| US-10665897-B2 | Lithium secondary battery including phosphite additive | SCO2, NIBAN2, SLC39A11 | ALDH1A1 4583/4885CA1 165/4885CA12 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.